Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Renal Cell 5Colorectal Neoplasms 4Gastrointestinal Neoplasms 2Solid Tumors 1Sarcoma 1Recurrence 1Neoplasms 1Glioblastoma 1Fallopian Tube Neoplasms 1Disease Progression 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Solid Tumors 1Advanced Adult Hepatocellular Carcinoma 1

Interventions

durvalumab 7Carboplatin 7Docetaxel 6Paclitaxel 5Nivolumab 5talazoparib 4linifanib 4Cisplatin 4trifluridine tipiracil drug combination 3tremelimumab 3tislelizumab 3depatuxizumab 3ST 1481 3S 1 (combination) 3Panobinostat 3Gemcitabine 3zimberelimab 2toripalimab 2olaparib 2motesanib diphosphate 2mogamulizumab 2TAS-114 2Sorafenib 2Rifampin 2PM 01183 2Oxaliplatin 2MLN 8237 2Itraconazole 2Injections 2Erlotinib Hydrochloride 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Solid Tumors × tivozanib × Clear all
NCT01210846 2011-09-26

A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors

AVEO Pharmaceuticals, Inc.

Phase 1 Completed
50 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡